Businesses, professional bodies and individual practitioners have to keep talking at a time like this, not least because patients’ non-Covid-related needs have not disappeared overnight. How are lines of communication holding up, and what might this tell us about life after Covid-19?

The first ever clinical study evaluating combined transcranial direct current stimulation (tDCS) and behaviour therapy could point to a new treatment for depression.

Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.

England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.

The U.S. FDA approved AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older during 2017.

With a goal of eradicating hepatitis C, NHS England has teamed up Gilead Sciences Inc., Merck & Co. and AbbVie Inc.

The U.S. government’s toll-free substance abuse helpline, which provides free referral services to those looking for treatment, gets little publicity, a new study finds.

Britain’s drug price watchdog rejected Novartis’ migraine drug Aimovig for now, concluding in a draft decision that the medicine was not a cost-effective use of National Health Service resources.

The number of new clinical trials started in Britain during 2017 was 25 percent lower than the average for 2009-2016, as anxiety about Brexit’s impact on future medicines regulation made companies hesitate about running studies in the country.

Health authorities in England agreed with Novartis to fast-track access to the Swiss drugmaker’s expensive CAR-T cell therapy Kymriah and make it available to children and young people with aggressive leukemia when other drugs have failed.